Physician profile
Tuan Pham
NPI 1366604423
$39,117.16
in general payments reported to CMS, 2019-2025
13 companies · $21K in 2025
The $21K reported for 2025 was more than what 75% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $22.57 · 2021: $86.60 · 2022: $155 · 2023: $595 · 2024: $17K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $8,600 · Food and Beverage: $3,582 · Travel and Lodging: $2,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,619.50 |
| Consulting Fee | $8,600.00 |
| Food and Beverage | $3,582.00 |
| Travel and Lodging | $2,618.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $35,112.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $2,002.70 | 2023-2025 | |
| Gilead Sciences, INC. | $859.57 | 2019-2024 | Livdelzi, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.69 | 2023-2025 | Xifaxan |
| Boston Scientific Corporation | $282.57 | 2025 | Overstitch Nxt Endoscopic Suturing System, Overstitch Endoscopic Suturing System |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| Eisai INC. | $122.26 | 2019 | |
| Intercept Pharmaceuticals, INC. | $97.73 | 2019 | |
| Apollo Endosurgery US INC | $82.33 | 2019 | |
| Cook Medical LLC | $58.68 | 2020-2021 | |
| Mirum Pharmaceuticals, INC. | $49.03 | 2024 | Livmarli |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuan Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.